Gene augmentation involves introducing a functional gene into a cell to compensate for a defective gene, while gene silencing, gene editing, and gene replacement all involve modifying or replacing a defective gene.

Monoclonal antibodies are designed to bind to specific antigens, such as those found on the surface of cancer cells or viruses, and neutralize their activity by preventing them from interacting with their targets.

Embryonic stem cells are pluripotent, meaning they have the potential to differentiate into all cell types in the body, including those found in the three germ layers: ectoderm, mesoderm, and endoderm.

The main advantage of using stem cells in regenerative medicine is their ability to differentiate into multiple cell types, which allows them to replace damaged or diseased cells and restore tissue function.

Gene therapy is primarily used for treating genetic disorders, developing new vaccines, and curing cancer. Enhancing athletic performance is not a legitimate application of gene therapy.

One of the main challenges associated with using monoclonal antibodies in cancer therapy is that cancer cells can develop resistance to the treatment over time, rendering the antibodies less effective.

While stem cell therapy has shown promise in treating spinal cord injuries, regenerating damaged heart tissue, and curing type 1 diabetes, there is no evidence to support its use in enhancing memory and cognitive function.

Gene replacement therapy involves replacing a defective gene with a functional copy, either by directly inserting the functional gene into the genome or by using a viral vector to deliver the gene to the target cells.

CAR T-cell therapy involves genetically modifying T cells to express chimeric antigen receptors (CARs), which enable the T cells to recognize and bind to specific antigens on cancer cells. This binding activates the T cells, causing them to attack and destroy the cancer cells.

Adult stem cells, specifically hematopoietic stem cells, are commonly used in bone marrow transplants to replenish the patient's blood-forming cells.

Monoclonal antibodies can be designed to target specific antigens on cancer cells, allowing them to selectively kill cancer cells while sparing healthy cells. This makes them more precise and less toxic than traditional chemotherapy drugs.

Viral vector-mediated gene transfer involves using a modified virus to deliver a functional gene to target cells. The virus is engineered to be non-replicative and to carry the therapeutic gene, which is then integrated into the host cell's genome.

One of the main challenges associated with using stem cells in regenerative medicine is the risk of immune rejection. Stem cells from a donor may be recognized as foreign by the patient's immune system, leading to rejection of the transplanted cells.

Hematopoietic stem cells, which are found in cord blood, are commonly used in cord blood transplants to replenish the patient's blood-forming cells.

Gene therapy has the potential to target the underlying genetic cause of a disease, offering the possibility of a permanent cure. Traditional drug therapy often only treats the symptoms of a disease, not the underlying cause.